Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis
Abstract Intra-patient variability in immunosuppressive blood drug concentrations is a potential biomarker in managing organ transplant patients. However, the association between the time in therapeutic range of tacrolimus blood concentrations and its efficacy in preventing graft-versus-host disease...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-87801-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571752572518400 |
|---|---|
| author | Naoki Yoshikawa Yukina Ehara Yusei Yamada Yuki Matsusaki Kazuya Shimoda Ryuji Ikeda |
| author_facet | Naoki Yoshikawa Yukina Ehara Yusei Yamada Yuki Matsusaki Kazuya Shimoda Ryuji Ikeda |
| author_sort | Naoki Yoshikawa |
| collection | DOAJ |
| description | Abstract Intra-patient variability in immunosuppressive blood drug concentrations is a potential biomarker in managing organ transplant patients. However, the association between the time in therapeutic range of tacrolimus blood concentrations and its efficacy in preventing graft-versus-host disease remains unknown. In this study, we analyzed the relationship between the time in therapeutic range of tacrolimus blood concentrations and its efficacy in acute graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Eligible patients administered tacrolimus were categorized into two groups based on the grade of acute graft-versus-host disease, and propensity score matching was performed using graft-versus-host disease prophylaxis protocols and days to the disease onset to compare time in therapeutic range. In patients with tacrolimus blood concentration therapeutic range ≥ 10 ng/mL, time in therapeutic range during the first 4 weeks post-transplantation was significantly lower in the Grade II–III than in the Grade 0–I group. Among propensity score matching-extracted patients, the Grade II–III group had significantly lower time in therapeutic range during the first 2 and 4 weeks post-transplantation. Our results suggest that high time in therapeutic range early post-transplantation, particularly within 4 weeks, may avert the severity of acute graft-versus-host disease. |
| format | Article |
| id | doaj-art-be3404c1f90646738932aa73f6e16bea |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-be3404c1f90646738932aa73f6e16bea2025-02-02T12:23:40ZengNature PortfolioScientific Reports2045-23222025-01-0115111110.1038/s41598-025-87801-2Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxisNaoki Yoshikawa0Yukina Ehara1Yusei Yamada2Yuki Matsusaki3Kazuya Shimoda4Ryuji Ikeda5Department of Pharmacy, University of Miyazaki HospitalDepartment of Pharmacy, University of Miyazaki HospitalDepartment of Pharmacy, University of Miyazaki HospitalDepartment of Pharmacy, University of Miyazaki HospitalDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDepartment of Pharmacy, University of Miyazaki HospitalAbstract Intra-patient variability in immunosuppressive blood drug concentrations is a potential biomarker in managing organ transplant patients. However, the association between the time in therapeutic range of tacrolimus blood concentrations and its efficacy in preventing graft-versus-host disease remains unknown. In this study, we analyzed the relationship between the time in therapeutic range of tacrolimus blood concentrations and its efficacy in acute graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Eligible patients administered tacrolimus were categorized into two groups based on the grade of acute graft-versus-host disease, and propensity score matching was performed using graft-versus-host disease prophylaxis protocols and days to the disease onset to compare time in therapeutic range. In patients with tacrolimus blood concentration therapeutic range ≥ 10 ng/mL, time in therapeutic range during the first 4 weeks post-transplantation was significantly lower in the Grade II–III than in the Grade 0–I group. Among propensity score matching-extracted patients, the Grade II–III group had significantly lower time in therapeutic range during the first 2 and 4 weeks post-transplantation. Our results suggest that high time in therapeutic range early post-transplantation, particularly within 4 weeks, may avert the severity of acute graft-versus-host disease.https://doi.org/10.1038/s41598-025-87801-2TacrolimusTherapeutic drug monitoringTime in therapeutic rangeHematopoietic stem cell transplantationGraft-versus-host disease |
| spellingShingle | Naoki Yoshikawa Yukina Ehara Yusei Yamada Yuki Matsusaki Kazuya Shimoda Ryuji Ikeda Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis Scientific Reports Tacrolimus Therapeutic drug monitoring Time in therapeutic range Hematopoietic stem cell transplantation Graft-versus-host disease |
| title | Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis |
| title_full | Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis |
| title_fullStr | Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis |
| title_full_unstemmed | Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis |
| title_short | Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis |
| title_sort | time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft versus host disease prophylaxis |
| topic | Tacrolimus Therapeutic drug monitoring Time in therapeutic range Hematopoietic stem cell transplantation Graft-versus-host disease |
| url | https://doi.org/10.1038/s41598-025-87801-2 |
| work_keys_str_mv | AT naokiyoshikawa timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis AT yukinaehara timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis AT yuseiyamada timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis AT yukimatsusaki timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis AT kazuyashimoda timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis AT ryujiikeda timeintherapeuticrangeoftacrolimusinallogeneichematopoieticstemcelltransplantrecipientsisassociatedwithacutegraftversushostdiseaseprophylaxis |